These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 4082636

  • 21. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 3rd communication: plasma concentrations of the unchanged drug and its deethylated metabolite in rats, dogs and monkeys.
    Nakamura A, Hirota T, Sugihara K, Morino A.
    Arzneimittelforschung; 1997 Feb; 47(2):169-74. PubMed ID: 9079236
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Metabolic fate of the beta-blocker 14C-bupranolol in humans, dogs, and rhesus monkeys.
    Waller AR, Chasseaud LF, Bonn R, Taylor T, Darragh A, Girkin R, Down WH, Doyle E.
    Drug Metab Dispos; 1982 Feb; 10(1):51-4. PubMed ID: 6124383
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetics of 4-acetylaminophenylacetic acid. 1st communication: absorption, distribution, metabolism and excretion in mice, rats, dogs and monkeys after single administration of 14C-labeled compound.
    Sugihara K, Morino A, Nomura A, Iida S, Sugiyama M.
    Arzneimittelforschung; 1990 Jul; 40(7):800-5. PubMed ID: 2222556
    [Abstract] [Full Text] [Related]

  • 26. Metabolic fate of 14C-camostat mesylate in man, rat and dog after intravenous administration.
    Midgley I, Hood AJ, Proctor P, Chasseaud LF, Irons SR, Cheng KN, Brindley CJ, Bonn R.
    Xenobiotica; 1994 Jan; 24(1):79-92. PubMed ID: 8165824
    [Abstract] [Full Text] [Related]

  • 27. The metabolic fate of [14C]oxaprotiline.HCl in man. I. Disposition and preliminary pharmacokinetics.
    Dieterle W, Faigle JW, Imhof P, Sulc M, Wagner J.
    Xenobiotica; 1984 Apr; 14(4):303-10. PubMed ID: 6464500
    [Abstract] [Full Text] [Related]

  • 28. Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs.
    Tokuma Y, Fujiwara T, Noguchi H.
    Xenobiotica; 1987 Nov; 17(11):1341-9. PubMed ID: 3433803
    [Abstract] [Full Text] [Related]

  • 29. Modipafant, a new PAF antagonist: pharmacokinetics and disposition in rat, dog and man.
    Jezequel SG, Uden S, Wastall P.
    Xenobiotica; 1996 Sep; 26(9):963-75. PubMed ID: 8893043
    [Abstract] [Full Text] [Related]

  • 30. The metabolic fate of the coronary vasodilator 4-(3,4,5-Trimethoxycinnamoyl)-1-(N-pyrrolidinocarbonylmethyl)piperazine (cinepazide) in the rat, dog and man.
    Cameron BD, Chasseaud LF, Hawkins DR, Taylor T.
    Xenobiotica; 1976 Jul; 6(7):441-55. PubMed ID: 997590
    [Abstract] [Full Text] [Related]

  • 31. The metabolism and excretion of (+)-[14C]cyanidanol-3 in man following oral administration.
    Hackett AM, Griffiths LA, Broillet A, Wermeille M.
    Xenobiotica; 1983 May; 13(5):279-86. PubMed ID: 6636824
    [Abstract] [Full Text] [Related]

  • 32. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.
    Ahr HJ, Boberg M, Brendel E, Krause HP, Steinke W.
    Arzneimittelforschung; 1997 Jun; 47(6):734-45. PubMed ID: 9239452
    [Abstract] [Full Text] [Related]

  • 33. Metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits, and dogs.
    Mamidi RN, Mannens G, Annaert P, Hendrickx J, Goris I, Bockx M, Janssen CG, Kao M, Kelley MF, Meuldermans W.
    Drug Metab Dispos; 2007 Apr; 35(4):566-75. PubMed ID: 17220243
    [Abstract] [Full Text] [Related]

  • 34. Metabolism of labetalol by animals and man.
    Martin LE, Hopkins R, Bland R.
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):695-710. PubMed ID: 990152
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.
    Okuyama Y, Momota K, Morino A.
    Arzneimittelforschung; 1997 Mar; 47(3):276-84. PubMed ID: 9105546
    [Abstract] [Full Text] [Related]

  • 36. The absorption, metabolism and excretion of (14C)-AR-L 115 BS in the baboon.
    Cameron BD, Draffan GH, Dunsire JP, Zimmer A.
    Arzneimittelforschung; 1981 Mar; 31(1a):217-20. PubMed ID: 7195225
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 4th communication: metabolism in rats and dogs.
    Hirota T, Nakamura A, Sugihara K, Morino A.
    Arzneimittelforschung; 1997 Feb; 47(2):175-81. PubMed ID: 9079237
    [Abstract] [Full Text] [Related]

  • 38. Metabolic fate of a new dihydropyridine calcium antagonist, CD-349, in rat and dog.
    Ogawa N, Mizuno K, Fukushima K, Suwa T, Satoh T.
    Xenobiotica; 1993 Jul; 23(7):747-59. PubMed ID: 8237057
    [Abstract] [Full Text] [Related]

  • 39. Metabolism of 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo [4,3-alpha] [1,4] benzodiazepine, triazolam, a new central depressant. I. Absorption, distribution and excretion in rats, dogs and monkeys.
    Kitagawa H, Esumi Y, Kurosawa S, Sekine S, Yokoshima T.
    Xenobiotica; 1979 Jul; 9(7):415-28. PubMed ID: 40350
    [Abstract] [Full Text] [Related]

  • 40. Disposition of the new antirheumatic agent ethyl 4-(3,4-dimethoxyphenyl)- 6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603) in rats and dogs.
    Tagawa Y, Kiyota Y, Yoshimura Y, Motohashi M, Tanayama S.
    Arzneimittelforschung; 1998 Jul; 48(7):750-7. PubMed ID: 9706376
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.